Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4A | O75164 | 2/20 | 0.43 |
| ▸ | KDM4B | O94953 | 2/20 | 0.43 |
| ▸ | KDM5C | P41229 | 2/20 | 0.43 |
| ▸ | KDM5B | Q9UGL1 | 2/20 | 0.43 |
| ▸ | METAP1 | P53582 | 4/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | METAP2 | P50579 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7964249 | 0.78 | TSHR (0.50) | KDM4AKDM4BKDM5CKDM5BMETAP1 | |
| SCHEMBL16720341 | 0.76 | KDM4A (0.37) | KDM4AKDM4BKDM5CKDM5BMETAP1 | |
| SCHEMBL1743331 | 0.75 | KDM4E (0.61) | KDM4AKDM4BKDM5CKDM5BMETAP1 | |
| SCHEMBL534231 | 0.74 | KDM4A (0.37) | KDM4AKDM4BKDM5CKDM5BMETAP1 | |
| SCHEMBL1849188 | 0.72 | MECP2 (0.43) | TSHRKDM4ENPC1TP53RAB9A | |
| SCHEMBL1555299 | 0.71 | KDM4A (0.37) | KDM4AKDM4BKDM5CKDM5BMETAP1 | |
| SCHEMBL27199211 | 0.70 | LRRK2 (0.34) | KDM4AKDM4BKDM5CKDM5BMETAP1 | |
| SCHEMBL14994553 | 0.70 | METAP1 (0.33) | KDM4AKDM4BKDM5CKDM5BMETAP1 | |
| SCHEMBL4533718 | 0.69 | CASP6 (0.45) | KDM4AKDM4BKDM5CKDM5BMETAP1 | |
| SCHEMBL21091024 | 0.69 | CASP6 (0.45) | KDM4AKDM4BKDM5CKDM5BMETAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105051019-B | Compound, electron transport material, and organic electroluminescent element using the electron transport material | 捷恩智株式会社 | 2018-06-12 | — | — | CN | disclosed |
| US-8481521-B2 | Methods of treating cell proliferative disorders | RIGEL PHARMACEUTICALS, INC. (US) | 2013-07-09 | — | — | US | disclosed |
| US-20120245127-A1 | Methods of Treating Cell Proliferative Disorders | RIGEL PHARMACEUTICALS, INC. (US) | 2012-09-27 | — | — | US | disclosed |
| US-8227455-B2 | Methods of treating cell proliferative disorders | RIGEL PHARMACEUTICALS, INC. (US) | 2012-07-24 | — | — | US | disclosed |
| US-7576053-B2 | treating osteoporosis caused by imbalance of osteoclast and osteoblast activity, glandular disorders with a Syk kinase inhibitor a 2,4-pyrimidinediamine compound; alendronate, calcitonin, estrogen and selective estrogen receptor modulators; side effect reduction | RIGEL PHARMACEUTICALS, INC. (US) | 2009-08-18 | — | — | US | disclosed |
| EP-1896134-A2 | METHODS AND COMPOSITIONS FOR TREATING DEGENERATIVE BONE DISORDERS | Rigel Pharmaceuticals, Inc. (US) | 2008-03-12 | — | — | EP | disclosed |
| US-20070004626-A1 | Methods and compositions for treating degenerative bone disorders | RIGEL PHARMACEUTICALS, INC. (US) | 2007-01-04 | — | — | US | disclosed |
| WO-2006135915-A2 | METHODS AND COMPOSITIONS FOR TREATING DEGENERATIVE BONE DISORDERS | RIGEL PHARMACEUTICALS, INC. (US) | 2006-12-21 | — | — | WO | disclosed |
| US-20060276459-A1 | Methods of treating cell proliferative disorders | RIGEL PHARMACEUTICALS, INC. (US) | 2006-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276459-A1 | Methods of treating cell proliferative disorders | MKI67, SYK, TP53 | KDM4A 1187/4885KDM4B 1438/4885KDM5C 1262/4885 |
| US-20120245127-A1 | Methods of Treating Cell Proliferative Disorders | MKI67, SYK, TP53 | KDM4A 1187/4885KDM4B 1438/4885KDM5C 1262/4885 |
| US-20070004626-A1 | Methods and compositions for treating degenerative bone disorders | SYK, TRAF6, BTK | KDM4A 1538/4885KDM4B 1488/4885KDM5C 680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.